Browse News
Filter News
Found 97 articles
-
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
6/29/2022
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design.
-
InflaRx to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference.
-
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
5/12/2022
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2022 and provided a business update.
-
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
3/31/2022
InflaRx N.V. announced today that the Phase III part of the Phase II/III PANAMO study with mechanically ventilated COVID-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9% (vilobelimab 31.7% versus placebo 41.6%, p=0.094).
-
InflaRx Reports Full Year 2021 Financial and Operating Results
3/24/2022
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced financial and operating results for the year ended December 31, 2021.
-
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
3/17/2022
InflaRx N.V. today reported that the Company has received a corrected advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS).
-
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
3/8/2022
InflaRx N.V. announced that final data from the Company’s Phase IIa open-label study with vilobelimab in patients with pyoderma gangrenosum (PG) will be presented at the 2022 American Academy of Dermatology Association (AAD) Annual Meeting , being held March 25-29 in Boston, MA USA.
-
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
2/28/2022
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received an advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS).
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
-
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
2/16/2022
InflaRx N.V. today announced the start of the second dosing cohort of the vilobelimab and PD-1 checkpoint inhibitor, pembrolizumab, combination arm of the Phase II clinical trial in cutaneous squamous cell carcinoma (cSCC).
-
InflaRx to Present at Annual SVB Leerink Global Health Conference
2/8/2022
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11th Annual SVB Leerink Healthcare Conference being held virtually February 14-18, 2022.
-
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
1/10/2022
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR.
-
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
1/5/2022
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa patients with active draining tunnels.
-
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
1/5/2022
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events.
-
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
11/15/2021
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV).
-
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
11/11/2021
InflaRx will present a corporate overview at the H.C. Wainwright 7th Annual Israel Conference. The session will take place virtually on Monday, November 15th at 8:00 am EST/2:00 pm CET
-
InflaRx Reports Third Quarter 2021 Financial & Operating Results
11/5/2021
InflaRx announced today financial and operating results for the three and nine months ended September 30, 2021.